Aderans Research Institute Inc. (ARI) said today it has expanded its clinical trials on hair regeneration by an additional seven cities in the United States.
Atlanta, GA (PRWEB) May 4, 2010 -- Aderans Research Institute Inc. (ARI) said today it has expanded its clinical trials on hair regeneration by an additional seven cities in the United States. Las Vegas, NV; Los Angeles, CA; and New Hyde Park, NY, have been added through clinical site company Impact Clinical Trials. Tucson, AZ; St. Louis, MO; Birmingham, AL; and St. Petersburg, FL, have been added through clinical site company Radiant Research.
Collectively, the Radiant and Impact sites will add around 80 new subjects to the study. Combined with at least twenty new additions at a site hosted by TKL Research, the second phase of ARI’s clinical study will surpass 200 subjects in total, a remarkable number of participants for a Phase 2 trial.
“The expansion of our study reflects not only the significance of the investment made by Aderans Co. Ltd of Japan, but also our confidence that we’re getting closer to a commercial viable solution to the problems of hair loss,” said Vern Liebmann, Vice President, Operations.
Added ARI Executive Vice President Ken Washenik M.D., Ph.D., “We’ve received some encouraging results from our initial Phase 2 studies and we’re eager to expand the trial, add new protocols, and refine our knowledge of the hair multiplication and regeneration process.”
Kurt Stenn M.D., Vice President of Research and Chief Scientific Officer, commented, “It is gratifying to see our research being steadily confirmed in our clinical work.”
Phase 2 launched in November of 2008. Phase 1 of ARI’s clinical study began in September of 2006 and concluded in February of 2008.